After selling Pathway Oncology and AKTivate to VHL for lofty sums does Paul Hopper really need/deserve to have his directorial pay doubled to $180k.
- Forums
- ASX - By Stock
- VHL
- Ann: Prescient completes acquisition of AKTivate Therapeutics
Ann: Prescient completes acquisition of AKTivate Therapeutics, page-2
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add VHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online